Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

It might not be a Dividend King, but AbbVie is no slacker when it comes to payments to its investors.

Forget Johnson & Johnson, AbbVie Is a Better Dividend Stock

AbbVie: Dividend Growth Stock Trading At A BIG Discount

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?

AbbVie (ABBV) Down 2% Since Last Earnings Report: Can It Rebound?

Why I Bought AbbVie Despite 43% Appreciation This Year

JPMorgan Chase & Co

Unilever

Earn some extra cash with these income-generating investments.

These 3 Dividend Stocks Could Bring You an Extra $100 a Month

Bristol-Myers

Eli Lilly

Merck

Pfizer

If you had gone off the grid in early January with no communication and just came back, you would see all the market indexes making new highs, but the levels are close to when you left.

Why Dividend-Paying Big Drug Companies May Be the Best Stocks to Own Now

AbbVie (ABBV) files an application to the FDA, seeking its nod for a new indication of Rinvoq, which is active ankylosing spondylitis. The drug is already marketed to treat rheumatoid arthritis.

AbbVie Seeks FDA Approval for Rinvoq in Ankylosing Spondylitis

GrowGeneration Corp

Green Thumb Industries Inc.

GW Pharmaceuticals

Village Farms International

You can find the best marijuana stocks to buy by considering their revenue rather than chasing pure hype. Here are six that fit the bill.

6 Marijuana Stocks to Buy That Are Sticking In the Green

NORTH CHICAGO, Ill., Aug. 25, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application for a new indication to the U.S.

AbbVie Submits Regulatory Application to FDA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis

AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases

AMC Entertainment

Cardlytics

DocuSign

Estee Lauder

Roku

Teladoc

Hot stocks are easy to find, but if you wait too long to buy them, you will have big regrets. Buy these seven stocks before it's too late.

7 Hot Stocks to Buy Before It’s Too Late

Gilead Sciences

Market Neutral Strategy: Long AbbVie, Short Gilead

Carlisle Companies

General Dynamics

Altria

SEI Investments

Sanofi

If You Like Attractively Valued Blue-Chips, You'll Love These 7 Dividend Growth Stocks

AbbVie: A Solid 5% Yield With The Potential For Growth

Since its spin-off from Abbott Laboratories in 2013, AbbVie has delivered strong dividend growth.

AbbVie: A Trifecta Of Yield, Growth, And Total Return Potential

3 Reasons AbbVie Is Ready To Bounce

Brookfield Infrastructure Partners L.P.

Duke Energy

You can sleep tight while the dividends pour in with these three stocks.

3 Dividend Stocks Yielding More Than 4% That Are Safe Buys Right Now

Eastman Chemical

Enbridge

Enterprise Products Partners

GenMark Diagnostics

Microsoft

Prudential Financial

Investing For The Long Run: Navigating A Bifurcated Market

AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are seeing strong sales uptake.

AbbVie Outperforms Large-Cap Pharma Industry Year to Date

NORTH CHICAGO, Ill., Aug. 12, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the publication of results from the Phase 3 VIALE-A clinical study in patients with AML in the New England Journal of Medicine (NEJM).

New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients

AstraZeneca

Johnson & Johnson

Novartis

Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes

AbbVie: Another Opportunity

Federal Realty Investment Trust

MetLife

Realty Income Corp

South Jersey Industries

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

The benchmark 10-year Treasury note yields just around 0.

7 Safe High-Yield Dividend Stocks Delivering 4% or More

5 Safe Ultra-High-Yield Blue-Chips For A Rich Retirement

Amgen

Boston Scientific

New products mean solid revenue may be ahead for these companies.

3 Top Healthcare Stocks to Buy in August

News for AbbVie Stock (ABBV)